Intensive care doctors use Efferon solutions as part of the complex therapy of sepsis, septic shock, and severe forms of coronavirus infection. These solutions are based on an original technology for producing highly effective polymer sorbents for extracorporeal blood purification.
In 2020, Efferon signed an agreement on joint work in the Russian market with the biopharmaceutical company Nanolek. Efferon is a resident of Skolkovo and the Moscow State University Science Park.
Alexander Volchansky, General Director of Efferon JSC:
“We have managed to create a full-cycle production of a globally competitive product. Our focus is on the rapidly growing demand in the home market, exports to Latin America, the European Union, the Middle East and China. Therefore, the immediate goal for 2021 is to scale up our production. In this regard, we welcome the emergence of a new partner, Fix Ventures.
Ivan Bessonov, technical director and co-founder of Efferon JSC:
“The global competitiveness of products like ours lies in the evidence base behind their prescription. It can be made up of two components. On the one hand, these are high-level clinical trials like the LASSO multicenter randomized trial initiated by us. On the other hand, it is“ real -worldevidence ”and conducting clinical trials in the format of“ global registries. ”We are confident that Fix Ventures competence in information technology and big data analysis will create new value here for us and our consumers. technologies, constant investments in research and development. We plan to further increase investments in these areas, in this matter, Dmitry Eremeev and I turned out to be like-minded people. ”
Dmitry Eremeev, founder of Fix Ventures and Bank 131:
“We are pleased to support a new Russian startup with a truly global product. The Efferon team has created and continues to improve solutions that are already saving and will help save the lives of many more serious patients. We believe in the excellent prospects of Efferon in the Russian and global markets. “Fix Ventures” intends to continue to support technologically and financially the growth of the company and its entry into new markets, and will continue to invest in other fast-growing Russian companies with global prospects. ”
Oleg Movsesyan, General Director of the Science Park of Moscow State University:
“I would like to congratulate our residents with a new round of investments – I am sure that the first“ unicorn ”represented by Efferon will soon appear in our ecosystem for the development of innovative companies. In a relatively short time, the company has gone from scientific development to a certified medical device that can successfully compete with the best world analogues. The Science Park assisted in the preparation and conduct of clinical trials of the dispensers, in cooperation with the doctors of the Moscow State University Medical Center and a number of Moscow hospitals – first of all, GKB 67 named after L.A. Vorokhobova. We will be happy to use our competencies and contacts for the successful promotion of the company’s products to world markets. The ecosystem for the development of innovative companies that has developed in the Science Park allows our residents to most effectively use the scientific and human potential of Moscow State University and achieve ambitious goals. Among the residents and graduates of the Science Park there are already several National Champions and winners of the TechUspekh rating of fast-growing innovative companies, and I am sure that the first unicorn will appear in the near future, possibly in the person of Efferon. We congratulate our colleagues and wish them a confident movement forward! “.
Vladimir Khristenko, President of Nanolek:
“It is important for us that the portfolio of Nanolek, which values its reputation and works with the largest global pharmaceutical companies, has Efferon hemosorption columns. This is a completely domestic product with a solid evidence base, which has been successfully used in the treatment of sepsis. Over the past year.” Efferon “managed to quickly gain recognition from the leading resuscitators of Russia – it is used in the treatment of severe forms of coronavirus. We are confident in the increased demand for this product and are ready to actively support its development in the Russian market.”
Source: Автономная некоммерческая организация "Редакция журнала «Наука и жизнь»" by www.nkj.ru.
*The article has been translated based on the content of Автономная некоммерческая организация "Редакция журнала «Наука и жизнь»" by www.nkj.ru. If there is any problem regarding the content, copyright, please leave a report below the article. We will try to process as quickly as possible to protect the rights of the author. Thank you very much!
*We just want readers to access information more quickly and easily with other multilingual content, instead of information only available in a certain language.
*We always respect the copyright of the content of the author and always include the original link of the source article.If the author disagrees, just leave the report below the article, the article will be edited or deleted at the request of the author. Thanks very much! Best regards!